RGLS
Regulus Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
EPS Beats Expectation
RSI Overbought
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RGLS
Regulus Therapeutics Inc.
A biopharmaceutical company that developing therapeutics to target microRNAs
4224 Campus Point Court, Suite 210, San Diego , CA 92121
--
Regulus Therapeutics Inc., was incorporated in Delaware on September 6, 2007. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of first-in-class drugs targeting microRNAs to treat diseases with significant medical needs.
Company Financials
EPS
RGLS has released its 2024 Q4 earnings. EPS was reported at -0.20, versus the expected -0.22, beating expectations. The chart below visualizes how RGLS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
